Potential pediatric applications of PET/MR

Journal of Nuclear Medicine

Volumn 55, Issue 6 SUPPL. 2, 2014, Pages

  Purz, Sandra ^a   Sabri, Osama ^a   Viehweger, Adrian ^b   Barthel, Henryk ^a   Kluge, Regine ^a   Sorge, Ina ^b   Hirsch, Franz Wolfgang ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Oncology; Pediatric oncology; Pediatrics; PET MR

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

ARTICLE; BONE TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CHILDHOOD CANCER; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; EPILEPSY; HUMAN; INFECTION; INFLAMMATORY DISEASE; LYMPHOMA; MOLECULAR IMAGING; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC CARDIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RADIATION EXPOSURE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR; TREATMENT RESPONSE; WHOLE BODY MRI; WHOLE BODY PET;

EID: 84903159202     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129304     Document Type: Article

References (80)

1. Glaudemans AW, Quintero AM, Signore A. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement? Eur J Nucl Med Mol Imaging. 2012;39:745-749.
2. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-336.
3. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med. 2008;38:199-208. (Pubitemid 351466918)
4. Bailey DL, Barthel H, Beyer T, et al. Summary Report of the First International Workshop on PET/MR Imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol. 2013;15:361-371.
5. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
6. Wiesmüller M, Quick HH, Navalpakkam B, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:12-21.
7. Schwenzer NF, Pfannenberg C, Reischl G, Werner MK, Schmidt H. Application of MR/PET in oncologic imaging [in German]. Rofo. 2012;184:780-787.
8. Hirsch FW, Sattler B, Sorge I, et al. PET/MR in children: initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013;43:860-875.
9. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol. 2014;83:84-94.
10. Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316-331. (Pubitemid 47247399)
11. Punwani S, Taylor SA, Saad ZZ, et al. Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol Imaging. 2013;40:373-385.
12. Darge K, Jaramillo D, Siegel MJ. Whole-body MRI in children: current status and future applications. Eur J Radiol. 2008;68:289-298.
13. Yankeelov TE, Peterson TE, Abramson RG, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn Reson Imaging. 2012;30:1342-1356.
14. Goo HW. Regional and whole-body imaging in pediatric oncology. Pediatr Radiol. 2011;41(suppl):S186-S194.
15. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244-1252.
16. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928-938.
17. 18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging. 2002;29:1155-1165.
18. Kluge R, Kurch L, Montravers F, Mauz-Körholz C. FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol. 2013;43:406-417.
19. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol. 2011;197:W384-W391.
20. Kluge R, Körholz D. Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Padiatr. 2011;223:315-319.
21. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging. 2011;38:274-284.
22. Krohmer S, Sorge I, Krausse A, et al. Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010;74:256-261.
23. Lin C, Luciani A, Itti E, et al. Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. Cancer Imaging. 2012;12:403-408.
24. 18F] fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol. 2011;29:3523-3528.
25. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:303-311.
26. 18F-FDG PET/MRI for staging and restaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2012;39:1745-1755.
27. Biederer J, Beer M, Hirsch W, et al. MRI of the lung (2/3). Why . . . when . . . how? Insights Imaging. 2012;3:355-371.
28. Hirsch W, Sorge I, Krohmer S, Weber D, Meier K, Till H. MRI of the lungs in children. Eur J Radiol. 2008;68:278-288.
29. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578. (Pubitemid 350002965)
30. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59. (Pubitemid 43053523)
31. 18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385-4391.
32. Bhatia S. Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors. Pediatrics. 2012;130:1141-1143.
33. Chen Y, Zhong J, Wu H, Chen N. The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging. 2012;30:165-170.
34. Kwee TC, Takahara T, Vermoolen MA, et al. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol. 2010;40:1592-1602.
35. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii100-vii109.
36. Denecke T, Hundsdörfer P, Misch D, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37:1842-1853.
37. 18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
38. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. Pediatr Radiol. 2012;42:418-430.
39. Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006;41:618-623. (Pubitemid 44284169)
40. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435-5441. (Pubitemid 350232220)
41. Hawkins DS, Spunt SL, Skapek SX; COG Soft Tissue Sarcoma Committee. Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer. 2013;60:1001-1008.
42. Servaes S, Epelman M, Pollock A, Shekdar K. Pediatric malignancies: synopsis of current imaging techniques. Cancer Treat Res. 2008;143:469-491.
43. Ricard F, Cimarelli S, Deshayes E, Mognetti T, Thiesse P, Giammarile F. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med. 2011;36:672-677.
44. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715-720. (Pubitemid 351231152)
45. Piperkova E, Mikhaeil M, Mousavi A, et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med. 2009;34:146-150.
46. Schuler MK, Richter S, Beuthien-Baumann B, et al. PET/MRI imaging in high-risk sarcoma: first findings and solving clinical problems. Case Rep Oncol Med. 2013;2013:793927.
47. Schnapauff D, Zeile M, Niederhagen MB, et al. Diffusion-weighted echo-planar magnetic resonance imaging for the assessment of tumor cellularity in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2009;29:1355-1359.
48. Sharp SE, Parisi MT, Gelfand MJ, Yanik GA, Shulkin BL. Functional-metabolic imaging of neuroblastoma. Q J Nucl Med Mol Imaging. 2013;57:6-20.
49. Mueller WP, Coppenrath E, Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol. 2013;43:418-427.
50. 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-1243.
51. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743-750.
52. Gains JE, Bomanji JB, Fersht NL, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041-1047.
53. Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013;60:65-70.
54. Leung D, Schwartz L. Imaging of neuroendocrine tumors. Semin Oncol. 2013;40:109-119.
55. Singhal T. Positron emission tomography applications in clinical neurology. Semin Neurol. 2012;32:421-431.
56. Garibotto V, Heinzer S, Vulliemoz S, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013;38:e13-e18.
57. Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for neurologic applications. J Nucl Med. 2012;53:1916-1925.
58. Freilich ER, Gaillard WD. Utility of functional MRI in pediatric neurology. Curr Neurol Neurosci Rep. 2010;10:40-46.
59. Schwaiger M, Wester HJ. How many PET tracers do we need? J Nucl Med. 2011;52(suppl):36S-41S.
60. Kim S, Salamon N, Jackson HA, Blüml S, Panigrahy A. PET imaging in pediatric neuroradiology: current and future applications. Pediatr Radiol. 2010;40:82-96.
61. 18F-FDG-PET and MRSI. J Neurooncol. 2012;109:521-527.
62. Gajjar A, Packer RJ, Foreman NK, et al. Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer. 2013;60:1022-1026.
63. Warren KE. Noninvasive assessment of pediatric brain tumors. Cancer Biol Ther. 2009;8:1881-1888.
64. Widjaja E, Shammas A, Vali R, et al. FDG-PET and magnetoencephalography in presurgical workup of children with localization-related nonlesional epilepsy. Epilepsia. 2013;54:691-699.
65. Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. Neuroradiology. 2013;55:541-550.
66. Seo JH, Holland K, Rose D, et al. Multimodality imaging in the surgical treatment of children with nonlesional epilepsy. Neurology. 2011;76:41-48.
67. Kim JT, Bai SJ, Choi KO, et al. Comparison of various imaging modalities in localization of epileptogenic lesion using epilepsy surgery outcome in pediatric patients. Seizure. 2009;18:504-510.
68. Rubí S, Setoain X, Donaire A, et al. Validation of FDG-PET/MRI coregistration in nonlesional refractory childhood epilepsy. Epilepsia. 2011;52:2216-2224.
69. Won HJ, Chang KH, Cheon JE, et al. Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. AJNR Am J Neuroradiol. 1999;20:593-599. (Pubitemid 30429014)
70. Vinton AB, Carne R, Hicks RJ, et al. The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. Brain. 2007;130:548-560. (Pubitemid 46181107)
71. Balink H, Collins J, Bruyn GA, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34:862-868.
72. 18F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. Eur J Nucl Med Mol Imaging. 2010;37:136-145.
73. 18F-FDG PET/CT in the diagnosis of occult bacterial infections in children. Eur J Pediatr. 2013;172:1111-1115.
74. 18F-FDG-PET with computed tomography in the diagnostic algorithm of patients with fever of unknown origin. Eur J Clin Microbiol Infect Dis. 2012;31:1727-1733.
75. 18F-FDG PET in children and adolescents. Klin Padiatr. 2013;225:212-217.
76. Ream JM, Dillman JR, Adler J, et al. MRI diffusion-weighted imaging (DWI) in pediatric small bowel Crohn disease: correlation with MRI findings of active bowel wall inflammation. Pediatr Radiol. 2013;43:1077-1085.
77. 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006;47:625-632.
78. Friedman AH, Fogel MA, Stephens P Jr, et al. Identification, imaging, functional assessment and management of congenital coronary arterial abnormalities in children. Cardiol Young. 2007;17:56-67. (Pubitemid 350237745)
79. Di Carli MF, Dorbala S. Cardiac PET-CT. J Thorac Imaging. 2007;22:101-106. (Pubitemid 46673162)
80. Jones T, Budinger TF. The potential for low-dose functional studies in maternal-fetal medicine using PET/MR imaging. J Nucl Med. 2013;54:2016-2017.